BCAL Diagnostics Limited (AU:BDX) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BCAL Diagnostics Limited has announced the launch of its wholly owned US subsidiary, BCAL Diagnostics, Inc., set to begin its operations on September 2, 2024. The expansion includes the strategic hire of Dr. Klaus-Peter Adam as Director of US Research and Product Development and the acquisition of vital equipment for a US research lab. This move is aimed at accelerating product development and gaining a deeper understanding of the US diagnostics market without the immediate need for additional capital, thanks to a recent successful capital raising effort.
For further insights into AU:BDX stock, check out TipRanks’ Stock Analysis page.